Tag Archive for: Novo Holdings

Weekly roundup: Insights, events, and industry moves

👥London Life Sciences Week 2025 The busiest week in European life sciences is approaching and Optimum and Catalyst Advisors are here to help you maximise your week. Download our events schedule here to plan ahead, connect smart, and make every moment count! If you have any additional events that you would like to be included, […]

Weekly roundup: Clearance, Capital & Copenhagen: A week in review!

AMS announced its Interim results for the six months ended 30 June 2025 This week Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announced its unaudited interim results for the six months ended 30 June 2025. Group revenue increased by 63% to ÂŁ110.8 million and by 66% at constant currency […]

Weekly roundup: An A* week! Advancements, acquisitions, appointments and Series A financings!

AMSilk Secures EUR 52M Strategic Financing to Accelerate Commercial Growth AMSilk GmbH has successfully secured EUR 52 million financing led by existing investor ATHOS (AT Newtec), along with strong participation from fellow existing investors MIG Capital and Novo Holdings. The financing will enable AMSilk to scale industrial production and meet global customer demand for its […]

AMSilk Secures EUR 52M Strategic Financing to Accelerate Commercial Growth

Funding enables AMSilk to scale industrial production and meet global customer demand for biotech produced silk-based protein materials The financing round was led by existing investor ATHOS (AT Newtec), with strong participation from fellow existing investors MIG Capital and Novo Holdings The total EUR 52M includes EUR 30M in cash and EUR 22M in convertible […]

Novo Holdings participates in $372.5 million Series D financing of MapLight Therapeutics to advance differentiated CNS therapies

Financing to support Phase 2 trials of lead program for schizophrenia and Alzheimer’s disease psychosis, and expansion of CNS pipeline San Francisco, US, 28 July 2025 – Novo Holdings, a leading life science investor, today announced its participation in a $372.5 million Series D financing of MapLight Therapeutics (“MapLight”), a clinical-stage biopharmaceutical company focused on improving […]